These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 35800156)

  • 1. Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.
    Wang Q; Ma X; Wu H; Zhao C; Chen J; Li R; Yan S; Li Y; Zhang Q; Song K; Yuan C; Kong B
    Oncoimmunology; 2022; 11(1):2096362. PubMed ID: 35800156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy.
    Fajardo CA; Guedan S; Rojas LA; Moreno R; Arias-Badia M; de Sostoa J; June CH; Alemany R
    Cancer Res; 2017 Apr; 77(8):2052-2063. PubMed ID: 28143835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
    de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
    J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity.
    Santos JM; Heiniö C; Cervera-Carrascon V; Quixabeira DCA; Siurala M; Havunen R; Butzow R; Zafar S; de Gruijl T; Lassus H; Kanerva A; Hemminki A
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
    Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
    J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
    Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
    Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
    Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
    Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
    J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy.
    Xie D; Tian Y; Hu D; Wang Y; Yang Y; Zhou B; Zhang R; Ren Z; Liu M; Xu J; Dong C; Zhao B; Yang L
    Signal Transduct Target Ther; 2023 Nov; 8(1):436. PubMed ID: 38016957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples.
    Scott EM; Jacobus EJ; Lyons B; Frost S; Freedman JD; Dyer A; Khalique H; Taverner WK; Carr A; Champion BR; Fisher KD; Seymour LW; Duffy MR
    J Immunother Cancer; 2019 Nov; 7(1):320. PubMed ID: 31753017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma.
    Morales-Molina A; Gambera S; Leo A; García-Castro J
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
    Speck T; Heidbuechel JPW; Veinalde R; Jaeger D; von Kalle C; Ball CR; Ungerechts G; Engeland CE
    Clin Cancer Res; 2018 May; 24(9):2128-2137. PubMed ID: 29437789
    [No Abstract]   [Full Text] [Related]  

  • 13. Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma.
    Huang J; Zheng M; Zhang Z; Tang X; Chen Y; Peng A; Peng X; Tong A; Zhou L
    Cancer Immunol Immunother; 2021 Sep; 70(9):2453-2465. PubMed ID: 33543339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.
    Freedman JD; Hagel J; Scott EM; Psallidas I; Gupta A; Spiers L; Miller P; Kanellakis N; Ashfield R; Fisher KD; Duffy MR; Seymour LW
    EMBO Mol Med; 2017 Aug; 9(8):1067-1087. PubMed ID: 28634161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antitumor immune response mediated by paclitaxel-conjugated nanohybrid oncolytic adenovirus with dendritic cell therapy.
    Kim IW; Yoon AR; Hong J; Kasala D; Yun CO
    Front Immunol; 2024; 15():1355566. PubMed ID: 38835775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas.
    Arnone CM; Polito VA; Mastronuzzi A; Carai A; Diomedi FC; Antonucci L; Petrilli LL; Vinci M; Ferrari F; Salviato E; Scarsella M; De Stefanis C; Weber G; Quintarelli C; De Angelis B; Brenner MK; Gottschalk S; Hoyos V; Locatelli F; Caruana I; Del Bufalo F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells.
    Hammer K; Kazcorowski A; Liu L; Behr M; Schemmer P; Herr I; Nettelbeck DM
    Int J Cancer; 2015 Aug; 137(4):978-90. PubMed ID: 25604186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma.
    Wang G; Zhang Z; Zhong K; Wang Z; Yang N; Tang X; Li H; Lu Q; Wu Z; Yuan B; Zheng M; Cheng P; Tong A; Zhou L
    Mol Ther; 2023 Jan; 31(1):134-153. PubMed ID: 36056553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioreducible polymer-mediated delivery of oncolytic adenovirus can attenuate antiviral immune response and concurrently enhance the induction of antitumor immune response to effectively prevent metastasis.
    Kasala D; Lee SH; Hong J; Oh E; Yoon AR; Yun CO
    Biomater Sci; 2022 Jul; 10(15):4293-4308. PubMed ID: 35766864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revolutionizing cancer treatment: the power of bi- and tri-specific T-cell engagers in oncolytic virotherapy.
    Zarezadeh Mehrabadi A; Tat M; Ghorbani Alvanegh A; Roozbahani F; Esmaeili Gouvarchin Ghaleh H
    Front Immunol; 2024; 15():1343378. PubMed ID: 38464532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.